Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.

Original reporting

finance.yahoo.com

Published Nov 6, 2026, 3:15 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 3:35 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$BDXBearishHigh

Why it matters

The guidance cut signals slower top‑line growth and flat margins, likely prompting a sell‑off in the short term.

Market read

New FY2027 guidance is material for investors; the quantified headwinds make the news highly relevant for trading decisions.

What to watch

Potential tariff relief under Section 232 could provide upside not reflected in the current guidance.

Relevance 8/10Novelty 8/10Timing: today

Background

The article is a transcript of Becton Dickinson's Q4 2026 earnings call, focusing on FY2027 guidance and operational challenges.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BDXBearishMedium confidence

Context

Becton Dickinson announced FY2027 revenue guidance of low single‑digit growth and flat operating margins, citing a 200‑bp Alaris headwind and EPS pressure.

Expected impact

downward pressure as investors price in slower growth and margin constraints

Evidence & confidence

Guidance is materially below prior expectations; the Alaris headwind is quantified, indicating near‑term earnings drag.

Market effects

Sector

Medical device sector may see broader pressure as peers with similar product lines face comparable margin headwinds.

Regional

U.S. healthcare investors likely adjust exposure; European and Asian markets less affected.

Global

Limited to healthcare investors; no immediate macro spillover.

Counterpoint

What could challenge this read

If the Alaris headwind eases faster than expected, the stock could rebound on the back of margin expansion.

Key entities

Company
Becton Dickinson & Co
Medical technology manufacturer providing the guidance.
Product Line
Alaris
Source of the quantified EPS and margin pressure.

Read at source ← All news

$BDXMed

Wells Fargo upgrades Becton Dickinson to Overweight from Equal-Weight, raises price target to $242 from $170

Wells Fargo upgraded Becton Dickinson to Overweight, raising its price target to $242 from $170, suggesting a 13.3% upside from the Nov 5 close of $213.55.

tradingview.comNov 6

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

finance.yahoo.comNov 6

$BDXMed

Wells Fargo upgrades Becton Dickinson stock rating on execution

Wells Fargo upgraded Becton Dickinson (BDX) to Overweight, raising its price target to $242. The company reported strong Q4 results, with revenue of $5.3B and EPS of $4.15, exceeding estimates. BDX has shown improved execution and conservative guidance for FY2027, with sales growth of 5.6% in Q4.

investing.comNov 6

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 2026 Earnings Call Summary

Becton, Dickinson (BD) reported Q4 2026 earnings, highlighting 27.3% adjusted EPS growth driven by revenue gains and cost savings. The company completed a life sciences spin-off, focusing on medtech. BD expects fiscal 2027 revenue growth of mid-single digits, with Q1 performance at the low end due to Alaris headwinds. Operating margins are projected to be flat. Management targets 90% free cash flow conversion and plans to return $3.6 billion to shareholders.

finance.yahoo.comNov 5

$BDXHigh

Jefferies raises Becton Dickinson stock price target on guidance

Jefferies raised its price target on Becton Dickinson (BDX) to $242 from $210, citing strong Q4 results and guidance. BDX reported $5.27B in sales, up 5.6%, and EPS of $4.15, up 27%. The company projected fiscal 2027 sales growth of low single digits and EPS of $13.10-$13.30. Jefferies views the guidance as conservative and sees potential upside. BDX stock has surged 55% over the past year.

investing.comNov 5

$BDXHighAI 8/10

BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat

Becton, Dickinson and Company (BDX) reported Q4 fiscal 2026 adjusted EPS of $4.15, up 27.3% YoY, and revenue of $5.27B, up 5.4% YoY, both exceeding estimates. All segments and regions showed growth, with Interventional leading. Despite strong results, BDX shares fell 6.4% in pre-market trading due to low-single-digit revenue growth guidance for fiscal 2027.

zacks.comNov 5